Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics
Retrieved on:
måndag, mars 25, 2024
Oak Ridge, TN, March 25, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it has entered into a definitive agreement to acquire exclusive and worldwide rights and intellectual property to manufacture from its existing supplier for Volumex and Megatope from privately-held Iso-Tex Diagnostics, Inc. Daxor has also acquired the exclusive rights to Glofil, a drug that measures glomerular filtration rate (GFR), which Iso-Tex has been selling directly to its customer base.
Key Points:
- Daxor projects the acquisitions to be cash flow positive and accretive to earnings immediately upon transfer of the manufacturing.
- This is due to the embedded revenue streams of the drugs and significantly higher margins that will be achieved with internalized production.
- No payments will come due until manufacturing is fully transitioned to Daxor over the next 6-9 months.
- The transaction is subject to customary conditions, including receipt of applicable regulatory approvals.